The following video is part of our "Motley Fool Conversations" series, in which David Williamson, health-care editor and analyst, and Brendan Byrnes, industrials editor and analyst, discuss topics across the investing world.
In today's edition, David and Brendan discuss the recent trend of biotech companies teaming up with generic manufacturers to create generic biologic drugs. There is currently no easy pathway to approval for biosimilars, but with one potentially coming thanks to the Affordable Care Act, we could see an increase of the cheaper drugs. How will this impact the industry going forward? Watch and find out.
David Williamson and Brendan Byrnes do not own shares of the companies listed above. The Motley Fool owns shares of Abbott Laboratories, Momenta Pharmaceuticals and Teva Pharmaceutical Industries. Motley Fool newsletter services recommend Momenta Pharmaceuticals. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.